KIBBUM KANG: Open Payments
NPI 1548502347 · GAINESVILLE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,061 in 32 payments from 15 companies in 2025. Trend: 2023 $292 · 2024 $637 · 2025 $1,061
Food & beverage: $1,061
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 6 | $273 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $143 |
| Gilead Sciences, Inc. | 1 | $122 |
| Phathom Pharmaceuticals, Inc. | 4 | $68 |
| Ardelyx, Inc. | 3 | $67 |
| Madrigal Pharmaceuticals | 2 | $65 |
| GENZYME CORPORATION | 2 | $64 |
| QOL Medical, LLC | 1 | $58 |
| ABBVIE INC. | 2 | $51 |
| Novo Nordisk Inc | 1 | $29 |
Products named: TREMFYA, XIFAXAN, Livdelzi, VOQUEZNA, IBSRELA, REZDIFFRA, DUPIXENT, Sucraid.
Industry payments across VA — which companies pay providers there.
